AKT1 and acute myeloid leukemia: Yang et al.‘s study in acute myeloid leukemia found that LINC00239 could activate the PI3K/Akt/mTOR signaling pathway to increase the resistance of acute myeloid leukemia cells to chemotherapeutic drugs [52].